Literature DB >> 15660270

High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.

Maxwell Afari Gyamfi1, Masaki Fujieda, Kazuma Kiyotani, Hiroshi Yamazaki, Tetsuya Kamataki.   

Abstract

OBJECTIVE: We investigated the frequencies of the functionally important variants of the CYP2A6 gene in black African populations.
METHODS: Using genomic DNA sequencing, polymerase chain reaction (PCR)-restriction fragment length polymorphism and allele-specific PCR, the allele frequencies of CYP2A6 *1A, *1B, *2, *4A, *5, *6, *7, *8, *9, *10 and * 11 among 120 black Africans- including 105 Ghanaians, 12 Nigerians, 2 Ivorians and 1 Ugandan-were determined.
RESULTS: The allele frequencies were 80.5% for CYP2A6*1A, 11.9% for CYP2A6*1B, 1.9% for CYP2A6*4A and 5.7% for CYP2A6*9 in the Ghanaian subjects. No subject homozygous for the CYP2A6*4A allele, a whole gene deletion type of polymorphism prevalent among Orientals, was found. Furthermore, CYP2A6 variants such as *2, *5, *6, *7, *8, *10 and *11 were absent in these black African populations.
CONCLUSIONS: This study provides, for the first time, the results of the analysis of CYP2A6 allele frequency in black African populations and confirms large ethnic differences in the polymorphic CYP2A6 gene.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660270     DOI: 10.1007/s00228-004-0854-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.

Authors:  N Ariyoshi; Y Takahashi; M Miyamoto; Y Umetsu; S Daigo; T Tateishi; S Kobayashi; Y Mizorogi; M A Loriot; I Stücker; P Beaune; M Kinoshita; T Kamataki
Journal:  Pharmacogenetics       Date:  2000-11

2.  An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles.

Authors:  C Xu; Y S Rao; B Xu; E Hoffmann; J Jones; E M Sellers; R F Tyndale
Journal:  Biochem Biophys Res Commun       Date:  2002-01-11       Impact factor: 3.575

Review 3.  Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19.

Authors:  S M Hoffman; D R Nelson; D S Keeney
Journal:  Pharmacogenetics       Date:  2001-11

4.  CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity.

Authors:  K Kitagawa; N Kunugita; M Kitagawa; T Kawamoto
Journal:  J Biol Chem       Date:  2001-02-16       Impact factor: 5.157

5.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.

Authors:  Ryoko Yoshida; Miki Nakajima; Yuki Watanabe; Jun-Tack Kwon; Tsuyoshi Yokoi
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

6.  A novel single nucleotide polymorphism altering stability and activity of CYP2a6.

Authors:  N Ariyoshi; Y Sawamura ; T Kamataki
Journal:  Biochem Biophys Res Commun       Date:  2001-03-02       Impact factor: 3.575

7.  Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.

Authors:  M Oscarson; R A McLellan; H Gullstén; J A Agúndez; J Benítez; A Rautio; H Raunio; O Pelkonen; M Ingelman-Sundberg
Journal:  FEBS Lett       Date:  1999-10-29       Impact factor: 4.124

8.  Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity.

Authors:  M Pitarque; O von Richter; B Oke; H Berkkan; M Oscarson; M Ingelman-Sundberg
Journal:  Biochem Biophys Res Commun       Date:  2001-06-08       Impact factor: 3.575

9.  Novel human CYP2A6 alleles confound gene deletion analysis.

Authors:  Miki Nakajima; Ryoko Yoshida; Tatsuki Fukami; Howard L McLeod; Tsuyoshi Yokoi
Journal:  FEBS Lett       Date:  2004-07-02       Impact factor: 4.124

10.  Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9).

Authors:  Kazuma Kiyotani; Hiroshi Yamazaki; Masaki Fujieda; Shunsuke Iwano; Keiko Matsumura; Soisungwan Satarug; Pailin Ujjin; Tsutomu Shimada; F Peter Guengerich; Andrew Parkinson; Goro Honda; Kazuko Nakagawa; Takashi Ishizaki; Tetsuya Kamataki
Journal:  Pharmacogenetics       Date:  2003-11
View more
  10 in total

Review 1.  Can pharmacogenomics improve malaria drug policy?

Authors:  Mary W Roederer; Howard McLeod; Jonathan J Juliano
Journal:  Bull World Health Organ       Date:  2011-09-01       Impact factor: 9.408

2.  Associations of CYP2A6 genotype with smoking behaviors in southern China.

Authors:  Tao Liu; Sean P David; Rachel F Tyndale; Hui Wang; Qian Zhou; Peng Ding; Yan-Hui He; Xue-Qing Yu; Wei Chen; Casey Crump; Xiao-Zhong Wen; Wei-Qing Chen
Journal:  Addiction       Date:  2011-05       Impact factor: 6.526

3.  High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.

Authors:  Eleni Aklillu; Natasa Djordjevic; Juan Antonio Carrillo; Eyasu Makonnen; Leif Bertilsson; Magnus Ingelman-Sundberg
Journal:  OMICS       Date:  2013-12-31

4.  Pharmacogenetics in Ghana: reviewing the evidence.

Authors:  W Kudzi; G O Adjei; D Ofori-Adjei; A N O Dodoo
Journal:  Ghana Med J       Date:  2011-06

5.  CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.

Authors:  Milimo Maimbo; Kazuma Kiyotani; Taisei Mushiroda; Collen Masimirembwa; Yusuke Nakamura
Journal:  Eur J Clin Pharmacol       Date:  2011-09-08       Impact factor: 2.953

Review 6.  PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6.

Authors:  Ellen M McDonagh; Catherine Wassenaar; Sean P David; Rachel F Tyndale; Russ B Altman; Michelle Whirl-Carrillo; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-09       Impact factor: 2.089

Review 7.  Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Authors:  Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2022-06-21

8.  CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Authors:  Awewura Kwara; Margaret Lartey; Kwamena W Sagoe; Naser L Rzek; Michael H Court
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

Review 9.  Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.

Authors:  Luis A López-Flores; Gloria Pérez-Rubio; Ramcés Falfán-Valencia
Journal:  EXCLI J       Date:  2017-03-06       Impact factor: 4.068

Review 10.  Revealing the paradox of drug reward in human evolution.

Authors:  Roger J Sullivan; Edward H Hagen; Peter Hammerstein
Journal:  Proc Biol Sci       Date:  2008-06-07       Impact factor: 5.349

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.